Nucleic Acid Therapeutics Market Size is valued at USD 4.93 billion in 2023 and is predicted to reach USD 13.86 billion by the year 2031 at a 13.8% CAGR during the forecast period for 2024-2031.
Nucleic acid therapeutics stands for a group of medicinal interventions that prevent illness by means of nucleic acids. Cutting-edge and focused therapies for a broad spectrum of hereditary and chronic diseases are now available through gene-targeting therapies. These therapies can fix mutations, regulate gene expression, and silence dangerous genes. Rising rates of chronic diseases and genetic conditions have prompted an upsurge of studies into ways to improve healthcare systems around the world, which bodes well for the sector. Additionally, the nucleic acid therapeutics business is being propelled forward by rising demand for pharmaceuticals and healthcare services, as well as new developments in biological goods and DNA therapies. However, strict rules regarding nucleic acid therapeutics are anticipated to impede the expansion of this industry. The ongoing development of novel and improved nucleic acid therapeutics is propelling market expansion.
However, due to the high treatment costs, stringent regulatory constraints, and a general lack of knowledge of nucleic acid treatments among both patients and healthcare professionals, the nucleic acid therapeutics industry is expected to slow down market growth. The rapid advancement of research and development, the increased focus on the efficacy of mRNA vaccines, and the surge in investment and interest in nucleic acid-based treatments for infectious diseases were all beneficial effects of the COVID-19 pandemic for the nucleic acid therapeutics business. Furthermore, the demand for nucleic acid therapeutics is expected to rise due to innovative treatments receiving substantial funding from pharmaceutical firms and governments.
The nucleic acid therapeutics market is segmented based on technology, application, and end-user. By technology, the market is segmented into RNA-targeted therapeutics, gene therapies, epigenetic and microRNA-modulating therapies, genome editing therapies, and others. By application, the market is segmented into autoimmune disorders, genetic disorders, infectious diseases, cancer, and others. As per the end-user segment, the market is categorized into hospitals and clinics, academic & research institutes, and others.
The RNA targeted therapeutics nucleic acid therapeutics category is expected to report a large global market share in 2023 due to its precision in targeting and modulating gene expression, notable progress in RNA technology, a surge in financing for RNA-based research, and the effective creation and authorization of RNA-based therapeutics for a range of illnesses, including gene diseases and viral infections.
The hospitals & clinics market is expected to grow rapidly in the nucleic acid therapeutics market because of the improved healthcare infrastructure, the ability of these facilities to deliver specialized care and efficiently administer complex medications, the increasing frequency of genetic and chronic diseases, and the increasing use of modern genetic treatments, which is growing the hospital & clinics segment growth.
The North American nucleic acid therapeutics market is estimated to register the maximum market share in revenue in the near future due to its state-of-the-art healthcare system, innovative treatments being readily available, and major expenditures on R&D by the pharmaceutical industry. The use of nucleic acid therapeutics is further encouraged by an increase in patient and healthcare provider understanding and comfort with these treatments. In addition, the Asia-Pacific region is expected to grow quickly in the global nucleic acid therapeutics market because of favourable government programs, a surge in investments in biotechnology, an uptick in genetic abnormalities, and a general increase in knowledge about cutting-edge medical therapies, which is growing the market demand in this area.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.97 Bn |
|
Revenue Forecast In 2031 |
USD 13.86 Bn |
|
Growth Rate CAGR |
CAGR of 13.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Technology, Application, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis, Moderna Inc, BioNTech, Arrowhead Pharmaceuticals, Merck, Thermo Fischer Scientific, Sanofi, Alnylam Pharmaceuticals, Sarepta Therapeutics, Qiagen, Imugene, and Copernicus Therapeutics Inc. and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nucleic Acid Therapeutics Market Snapshot
Chapter 4. Global Nucleic Acid Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Technology Estimates & Trend Analysis
5.1. by Technology& Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
5.2.1. RNA targeted therapeutics
5.2.2. Gene Therapies
5.2.3. Epigenetic and microRNA modulating therapies
5.2.4. Genome editing therapies
5.2.5. Others
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Autoimmune Disorders
6.2.2. Genetic Disorders
6.2.3. Infectious Diseases
6.2.4. Cancer
6.2.5. Others
Chapter 7. Market Segmentation 3: by End User Estimates & Trend Analysis
7.1. by End User & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End User:
7.2.1. Hospitals & Clinics
7.2.2. Academic & Research Institutes
7.2.3. Others
Chapter 8. Nucleic Acid Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.1.2. North America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.1.3. North America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.1.4. North America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.2.2. Europe Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.3. Europe Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.2.4. Europe Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.3.2. Asia Pacific Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.3. Asia-Pacific by End User, Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts 2024-2031
8.3.4. Asia Pacific Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.4.2. Latin America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.3. Latin America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.4.4. Latin America Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
8.5.2. Middle East & Africa Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.3. Middle East & Africa Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.5.4. Middle East & Africa Nucleic Acid Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novartis
9.2.2. Moderna Inc
9.2.3. BioNTech
9.2.4. Arrowhead Pharmaceuticals
9.2.5. Merck
9.2.6. Thermo Fischer Scientific
9.2.7. Sanofi
9.2.8. Alnylam Pharmaceuticals
9.2.9. Sarepta Therapeutics
9.2.10. Qiagen
9.2.11. Imugene
9.2.12. Copernicus Therapeutics Inc.
9.2.13. Protagonist Therapeutics
9.2.14. Arbutus Biopharma
9.2.15. Agilent Technologies
9.2.16. Silence Therapeutics (UK),
9.2.17. Astellas Pharma Inc. (Japan),
9.2.18. CureVac SE (Germany),
9.2.19. Sirnaomics (US),
9.2.20. Arcturus Therapeutics Inc. (US)
9.2.21. Other Prominent Players
Nucleic Acid Therapeutics Market By Technology-
Nucleic Acid Therapeutics Market By Applications-
Nucleic Acid Therapeutics Market By End-User-
Nucleic Acid Therapeutics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
